An experimental drug called selinexor made by Karyopharm Therapeutics (KPTI) hastened the death of patients with an advanced form of leukemia, but the company never publicly disclosed the negative outcome observed in the randomized clinical trial.
Karyopharm stopped the selinexor clinical trial prematurely in 2017 but the higher death rate was not revealed until Friday, when the Food and Drug Administration disclosed it as part of a skeptical review that could stop the drug from reaching the market.
That also means Karyopharm joins the growing list of biotechs — Trevena, Clovis Oncology, and Aveo Biopharma, among the most recent — caught hiding adverse information about experimental drugs until being outed by the FDA.
About the Author Reprints
